Organization
Bristol-Myers Squibb, Rueil-Malmaison, France
4 abstracts
Abstract
ADHERENCE TO THE RECOMMENDED DOSING REGIMEN OF ABATACEPT: RESULTS FROM THE INTERNATIONAL, REAL-WORLD ACTION STUDY Org: Chiltern International, Neuilly, Docs International, Sèvres, Bristol-Myers Squibb, Munich, Germany, Bristol-Myers Squibb, Rueil-Malmaison, France,
Abstract
ASSOCIATION BETWEEN CONVERSION TO ACPA/RF SERONEGATIVE STATUS AND CLINICAL OUTCOMES FOLLOWING TREATMENT WITH ABATACEPT IN COMBINATION WITH METHOTREXATE COMPARED WITH METHOTREXATE ALONE IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS AND POOR PROGNOSTIC INDICOrg: Bristol-Myers Squibb, Rueil-Malmaison, France, Bristol-Myers Squibb, Princeton, United States,
Abstract
ABATACEPT IMPROVES DISEASE ACTIVITY STATUS OVER TIME IN PATIENTS WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO METHOTREXATE Org: Hosp Cochin, Descartes Univ, Paris, France, Albany Medical College, Albany, NY, United States, Bristol-Myers Squibb, Rueil-Malmaison, France, Bristol-Myers Squibb, NJ, United States, Univ of Leeds, Leeds, United Kingdom,
Abstract
ASCORE, A 2-YEAR, OBSERVATIONAL, PROSPECTIVE MULTICENTRE STUDY OF SUBCUTANEOUS ABATACEPT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN ROUTINE CLINICAL PRACTICE: 1-YEAR INTERIM ANALYSISOrg: University Medicine Berlin, Berlin, Germany, Université Paris-Sud, Paris, France, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, University of Pavia and IRCCS S. Matteo Foundation, Pavia, Italy, Centre Hospitalier Universitaire de France, Lille, France,